1st October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Pharma association tells Karnataka HC; drug samples offered to doctors not freebies

In response to a PIL filed by the Karnataka Drugs and Pharmaceuticals Association and a few pharmaceutical companies, the high court ordered the issuance of notice to the Centre (finance ministry)

Typbar-TCV, a single dose conjugate vaccine for typhoid fever, patented by Bharat Biotech

Indian Patent Office has approved a patent application submitted by Hyderabad-based biotechnology company Bharat Biotech International Ltd for its single dose conjugate vaccine Typbar-TCV, for the prevention of typhoid fever.

To prevent premature nerve cell death, USFDA approved this drug

Amylyx Pharma announced that the US Food and Drug Administration (USFDA) had approved its drug for slowing the progression of ALS, or amyotrophic lateral sclerosis, and possibly postponing death.

Vibha Paul Rishi elected to board of directors of Piramal Pharma

The appointment of Vibha Paul Rishi to the board of directors of Piramal Pharma Limited (PPL) has been made public. An expert in marketing, Vibha has held global leadership positions in branding, strategy, innovation, and human resources.

Rapid IVD kits market in India expected to grow steadily

Over the forecast period FY’2022-27, the Indian Rapid IVD kits market is predicted to expand at a steady rate with a CAGR of 19.9%. The demand for point-of-care diagnostics is rising, and this demand is being fueled by rapidly advancing technology.

Lupin gains 4.5% after US FDA approves new drug to treat overactive bladder

Following the company’s receipt of USFDA approval for Mirabegron Tablets or Generic Myrbetrig, Lupin’s share price increased by nearly 4.5% to Rs 682 per share levels on the BSE and NSE intraday, respectively, during Friday’s trading session.

Late-stage trial of Intercept's NASH drug fails

According to Intercept Pharmaceuticals, a late-stage study’s primary objective was not achieved by its treatment for patients with advanced liver scarring brought on by nonalcoholic steatohepatitis (NASH).

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?